Affirm Holdings Inc. surpassed analysts' expectations with strong Q1 fiscal 2026 results, triggering a 9% surge in shares. This growth reflects a robust financial performance, including a 42% rise in Gross Merchandise Volume and increase in active consumers. Despite a conservative Q2 forecast, Affirm's raised full-year guidance signals continued profitability and market strength. Read more

Discover RBC Capital's bullish outlook on Viridian Therapeutics (VRDN), predicting a potential 63.64% increase in its stock price, driven by strategic initiatives and positive financial positioning. Amid reduced competition from Roche's Enspryng, find out how Viridian emerges as a promising player in the biotech sector. Read more